Skip to main content
. Author manuscript; available in PMC: 2021 May 17.
Published in final edited form as: Nat Med. 2020 May 11;26(5):688–692. doi: 10.1038/s41591-020-0856-x

Extended Data Fig. 1 |. Statistical identification of a baseline serum IL-8 cutoff below which patients were more likely to benefit from Nivo-based therapy.

Extended Data Fig. 1 |

ROC curve analyses were used to assess ORR, 6-month PFS, and 12-month OS. OS AUC (12-month) is indicated and identifies ≥23 pg/ml as a cutoff. All cases with nivolumab-containing therapies were analyzed. AUC, area under the curve; Nivo, nivolumab; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; ROC, receiver operator characteristic.